In the CheckMate 227 study, the combined use of nivolumab and ipilimumab significantly increased the median OS, decreased the risk of death, and increased the percentage of patients with 4-year survival compared to chemotherapy in all groups of patients differing in the expression of PD-L1 on tumor cells. The gene discussed is CD274; the disease is neoplasm.